ORIZURU THERAPEUTICS

Established in 2021 with the aim of promoting the social implementation of iPS cell technology.

At Orizuru Therapeutics, we conduct our business in accordance with the following principles:

Bringing Hope for Better Health through
the infinite Power of Science
To deliver innovative iPS cell-based therapies, OZTx will orchestrate R&D operations with strategic partners.
Deliver regenerative medicine to patients through iPS cell technology

Objectives and Stakeholders

Business Objectives

Development of regenerative medicine products utilizing transplantation of iPS cell derived cells
Advancement of drug discovery and establishment of a research infrastructure for regenerative medicine through the application of iPS cell technology
Initiatives to promote the social acceptance of iPS-derived therapies

Key Stakeholders

Medical professionals engaged in patient care and clinical practice
Our employees, who drive innovation and growth
The local communities and broader society to which we are accountable

Background of the Orizuru Therapeutics and T-CiRA

The discovery of induced pluripotent stem cells (iPS cells) in 2006 had a strong influence on the development of stem cell research and opened the infinite possibilities for drug discovery and regenerative medicine.
To develop clinical applications of iPS cells, CiRA at Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) have been conducting the “Takeda-CiRA Joint Program for iPS Cell Applications” (T-CiRA) since its agreement in 2015.
As the program progresses, a new framework is required to accelerate the realization of iPS cell-based therapeutics in a timely and effective manner, and Orizuru Therapeutics was established as one such approach. Orizuru Therapeutics will promote technological innovation and utilization of iPS cells and their related platforms, and contribute to the development of new therapeutic options.